CoChat
Sign Up
Cited by 69

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Circulating Dickkopf-1 in acute ischemic stroke and clinically stable cerebrovascular disease

Seifert-Held, Thomas, Pekar, Thomas, Gattringer, Thomas, Simmet, Nicole E., Scharnagl, Hubert, Stojakovic, Tatjana, Fazekas, Franz, Storch, Maria K.·2011·Atherosclerosis
DOI 10.1016/j.atherosclerosis.2011.05.015
Open this paper in CoChat — free account

Abstract

Objectives Previous data suggest that Dickkopf-1 (Dkk-1), an inhibitor of the canonical/β-catenin cascade of the Wnt pathway, is upregulated in carotid atherosclerosis and acute myocardial ischemia. It is currently unclear if such upregulation also occurs in cerebral ischemia. Methods We measured plasma levels of Dkk-1 in patients with acute ischemic stroke (n=57) within 24h from symptom onset, in patients with clinically stable cerebrovascular disease (n=29) and in healthy controls (n=29). Stroke severity on admission was determined by the National Institutes of Stroke Scale (NIHSS). The modified Rankin Scale (mRS) served to define outcome at day 90. Ischemic stroke subtype and cause was determined by the Oxfordshire Community Stroke Project (OCSP) criteria and the Causative Classification of Stroke System (CCS). Results Dkk-1 plasma levels were significantly higher in acute stroke patients (median 727.1 pg/ml) as compared to patients with stable cerebrovascular disease (median 534.2 pg/ml; p=0.017) or healthy controls (median 371.3 pg/ml; p Conclusion Our study provides for the first time evidence for a release of Dkk-1 into the circulation in patients with acute ischemic stroke and also in patients with clinically stable cerebrovascular disease.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.atherosclerosis.2011.05.015

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 27

  1. Sidow, 1992, Diversification of the Wnt gene family on the ancestral lineage of vertebrates, Proc Natl Acad Sci U S A, 89, 5098, 10.1073/pnas.89.11.5098 · DOI
  2. Kawano, 2003, Secreted antagonists of the Wnt signalling pathway, J Cell Sci, 116, 2627, 10.1242/jcs.00623 · DOI · Paper page
  3. Ueland, 2009, Dickkopf-1 enhances inflammatory interaction between platelets and endothelial cells and shows increased expression in atherosclerosis, Arterioscler Thromb Vasc Biol, 29, 1228, 10.1161/ATVBAHA.109.189761 · DOI
  4. Perez Castrillon, 2010, Levels of DKK1 in patients with acute myocardial infarction and response to atorvastatin, Int J Cardiol, 145, 164, 10.1016/j.ijcard.2009.07.025 · DOI
  5. Ingraham, 2011, Matrix metalloproteinase (MMP)-9 induced by Wnt signaling increases the proliferation and migration of embryonic neural stem cells at low O2 levels, J Biol Chem, 286, 17649, 10.1074/jbc.M111.229427 · DOI
  6. Cappuccio, 2005, Induction of Dickkopf-1, a negative modulator of the Wnt pathway, is required for the development of ischemic neuronal death, J Neurosci, 25, 2647, 10.1523/JNEUROSCI.5230-04.2005 · DOI
  7. Mastroiacovo, 2009, Induction of the Wnt antagonist Dickkopf-1, contributes to the development of neuronal death in models of brain focal ischemia, J Cereb Blood Flow Metab, 29, 264, 10.1038/jcbfm.2008.111 · DOI
  8. Rosi, 2010, Increased Dickkopf-1 expression in transgenic mouse models of neurodegenerative disease, J Neurochem, 112, 1539, 10.1111/j.1471-4159.2009.06566.x · DOI
  9. Caricasole, 2004, Induction of Dickkopf-1, a negative modulator of the Wnt pathway, is associated with neuronal degeneration in Alzheimer's brain, J Neurosci, 24, 6021, 10.1523/JNEUROSCI.1381-04.2004 · DOI
  10. Brott, 1989, Measurements of acute cerebral infarction: a clinical examination scale, Stroke, 20, 864, 10.1161/01.STR.20.7.864 · DOI
  11. van Swieten, 1988, Interobserver agreement for the assessment of handicap in stroke patients, Stroke, 19, 604, 10.1161/01.STR.19.5.604 · DOI · Paper page
  12. Quinn, 2009, Functional outcome measures in contemporary stroke trials, Int J Stroke, 4, 200, 10.1111/j.1747-4949.2009.00271.x · DOI
  13. Janssen, 2010, Comparison of telephone and face-to-face assessment of the modified Rankin Scale, Cerebrovasc Dis, 29, 137, 10.1159/000262309 · DOI
  14. Bamford, 1991, Classification and natural history of clinically identifiable subtypes of cerebral infarction, Lancet, 337, 1521, 10.1016/0140-6736(91)93206-O · DOI · Paper page
  15. Ay, 2007, A computerized algorithm for etiologic classification of ischemic stroke: the causative classification of stroke system, Stroke, 38, 2979, 10.1161/STROKEAHA.107.490896 · DOI
  16. Arsava, 2010, The Causative Classification of Stroke system: an international reliability and optimization study, Neurology, 75, 1277, 10.1212/WNL.0b013e3181f612ce · DOI
  17. Voorzanger-Rousselot, 2009, Platelet is a major contributor to circulating levels of Dickkopf-1: clinical implications in patients with multiple myeloma, Br J Haematol, 145, 264, 10.1111/j.1365-2141.2009.07587.x · DOI
  18. Kammersgaard, 1999, Leukocytosis in acute stroke: relation to initial stroke severity, infarct size, and outcome: the Copenhagen Stroke Study, J Stroke Cerebrovasc Dis, 8, 259, 10.1016/S1052-3057(99)80076-7 · DOI
  19. Sondergaard, 2009, A phase II clinical trial does not show that high dose simvastatin has beneficial effect on markers of bone turnover in multiple myeloma, Hematol Oncol, 27, 17, 10.1002/hon.869 · DOI
  20. Katan, 2009, Copeptin: a novel, independent prognostic marker in patients with ischemic stroke, Ann Neurol, 66, 799, 10.1002/ana.21783 · DOI
  21. Katan, 2010, Midregional pro-atrial natriuretic peptide and outcome in patients with acute ischemic stroke, J Am Coll Cardiol, 56, 1045, 10.1016/j.jacc.2010.02.071 · DOI
  22. Ferrari, 2010, Stroke thrombolysis: having more time translates into delayed therapy: data from the Austrian Stroke Unit Registry, Stroke, 41, 2001, 10.1161/STROKEAHA.110.590372 · DOI
  23. Medinger, 2011, Increased Dkk3 protein expression in platelets and megakaryocytes of patients with myeloproliferative neoplasms, Thromb Haemost, 105, 72, 10.1160/TH10-03-0172 · DOI
  24. Giles, 2003, Caught up in a Wnt storm: Wnt signaling in cancer, Biochim Biophys Acta, 1653, 1
  25. Qian, 2007, Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myeloma, Blood, 110, 1587, 10.1182/blood-2007-03-082529 · DOI
  26. Choi, 2009, Promising bone-related therapeutic targets for rheumatoid arthritis, Nat Rev Rheumatol, 5, 543, 10.1038/nrrheum.2009.175 · DOI
  27. Fulciniti, 2009, Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma, Blood, 114, 371, 10.1182/blood-2008-11-191577 · DOI

Cited by

Sorted by citations

Metadata

Authors
Seifert-Held, T., Pekar, T., Gattringer, T., Simmet, N. E., Scharnagl, H., Stojakovic, T., Fazekas, F., & Storch, M. K.
Venue
Atherosclerosis
Publisher
Elsevier BV
Published
2011-09
Volume
218
Issue
1
Pages
233-237
ISSN
0021-9150
DOI
10.1016/j.atherosclerosis.2011.05.015
Cited by
69
References
3
Language
en
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review